Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges

Louise Conilh; Virginia Metrangolo; Silvia Crescioli; Janice M. Reichert; Charles Dumontet

doi:10.1016/j.cell.2026.04.016

Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges

Louise Conilh
, Virginia Metrangolo
, Silvia Crescioli
, Janice M. Reichert
, Charles Dumontet^*

^*Corresponding author for this work

The Finsen Laboratory

7 Citations (Scopus)

Abstract

Antibody-drug conjugates are among the fastest-growing anticancer therapies, delivering potent payloads directly to tumor cells with improved safety across hematologic and solid tumors. This review focuses on their biology and where the field needs to move as they expand into earlier-stage use and combinations that heighten the need for careful patient selection and toxicity management.

Original language	English
Journal	Cell
Volume	189
Issue number	10
Pages (from-to)	2791-2820
Number of pages	30
ISSN	0092-8674
DOIs	https://doi.org/10.1016/j.cell.2026.04.016
Publication status	Published - 14 May 2026

Access to Document

10.1016/j.cell.2026.04.016

Cite this

@article{2cca0b8a2fd44b22ab27f0b80b5b605f,

title = "Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges",

abstract = "Antibody-drug conjugates are among the fastest-growing anticancer therapies, delivering potent payloads directly to tumor cells with improved safety across hematologic and solid tumors. This review focuses on their biology and where the field needs to move as they expand into earlier-stage use and combinations that heighten the need for careful patient selection and toxicity management.",

author = "Louise Conilh and Virginia Metrangolo and Silvia Crescioli and Reichert, \{Janice M.\} and Charles Dumontet",

note = "Publisher Copyright: {\textcopyright} 2026 Elsevier Inc.",

year = "2026",

month = may,

day = "14",

doi = "10.1016/j.cell.2026.04.016",

language = "English",

volume = "189",

pages = "2791--2820",

journal = "Cell",

issn = "0092-8674",

publisher = "Elsevier BV",

number = "10",

}

TY - JOUR

T1 - Navigating the clinical progress of antibody-drug conjugates

T2 - Emerging opportunities and remaining challenges

AU - Conilh, Louise

AU - Metrangolo, Virginia

AU - Crescioli, Silvia

AU - Reichert, Janice M.

AU - Dumontet, Charles

PY - 2026/5/14

Y1 - 2026/5/14

N2 - Antibody-drug conjugates are among the fastest-growing anticancer therapies, delivering potent payloads directly to tumor cells with improved safety across hematologic and solid tumors. This review focuses on their biology and where the field needs to move as they expand into earlier-stage use and combinations that heighten the need for careful patient selection and toxicity management.

AB - Antibody-drug conjugates are among the fastest-growing anticancer therapies, delivering potent payloads directly to tumor cells with improved safety across hematologic and solid tumors. This review focuses on their biology and where the field needs to move as they expand into earlier-stage use and combinations that heighten the need for careful patient selection and toxicity management.

UR - https://www.scopus.com/pages/publications/105038438145

U2 - 10.1016/j.cell.2026.04.016

DO - 10.1016/j.cell.2026.04.016

M3 - Review

C2 - 42134305

AN - SCOPUS:105038438145

SN - 0092-8674

VL - 189

SP - 2791

EP - 2820

JO - Cell

JF - Cell

IS - 10

ER -

Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges

Abstract

Access to Document

Other files and links

Fingerprint

Cite this